Valeant Pharmaceuticals International

953 articles about Valeant Pharmaceuticals International

• Bausch Health Announces Closing Of Incremental Amendment To Its Existing Credit Agreement And Redemption Of Its 7.500% Senior Notes Due 2021

  11/27/2018

  Bausch Health Companies Inc. announced today that it has entered into an incremental term loan facility amendment (the "Incremental Amendment") to its credit agreement, pursuant to which Valeant Pharmaceuticals International ("VPI"), a Delaware corporation and a wholly owned indirect subsidiary of the Company, borrowed $1,500,000,000 of new term B loans.

• Perrigo Confirms Patent Challenge for Generic Version of Jublia® Topical Solution 10%

  10/1/2018

  Perrigo Company plc today announced that, Valeant Pharmaceuticals North America LLC, Valeant Pharmaceuticals Ireland LTD., Dow Pharmaceuticals Sciences, Inc., and Kaken Pharmaceuticals Co., LTD, initiated patent litigation on September 21, 2018 in the United States District Court for the District

• 

  FDA Action Alert: Ortho Dermatologics, Akcea Therapeutics and Merck

  10/1/2018

  It looks to be a pretty busy week for the U.S. Food and Drug Administration (FDA), with a number of target action dates for various drugs. Some were delayed, and some were already approved, but there are still a number on the schedule. Here’s a look.
• 

  With Phase II Win for Ankylosing Spondylitis, Gilead and Galapagos' Filgotinib Inches Toward Appr...

  9/6/2018

  Gilead Sciences and its partner Galapagos NV announced results from its Phase II TORTUGA clinical trial of filgotinib, a selective JAK1 inhibitor, in adults with moderately to severely active ankylosing spondylitis (AS).
• 

  FDA Action Alert: Ortho Dermatologics, Tetraphase Pharma, Akcea and More

  8/27/2018

  This week has several action dates by the U.S. Food and Drug Administration (FDA) for a range of indications, including acne, intra-abdominal infections, and rare liver diseases. Here’s a look.

• Ekso Bionics Appoints Jack Glenn as Chief Financial Officer

  8/13/2018

  Ekso Bionics Holdings, Inc. (NASDAQ: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that John (Jack) Glenn has been appointed to the position of Chief Financial Officer.

• Strategic appointment expands Atlantic Healthcare executive team

  8/2/2018

  Atlantic Healthcare plc (Atlantic Healthcare), a specialist gastrointestinal (GI) pharmaceutical company, developing treatments for inflammatory bowel disease and other GI diseases, has appointed John Temperato as U.S. President and Chief Operating Officer, to lead the commercialisation programme of alicaforsen in the U.S.

• Virtus Thwarts Efforts of Bausch Health (formerly known as Valeant) to Push Lower Priced Competing Drugs off the Market

  8/2/2018

  Virtus Pharmaceuticals, LLC continues its efforts to provide consumers with access to lower cost drugs in the pharmaceutical industry, this time by prevailing in a case against Bausch Health Companies (formerly Valeant Pharmaceuticals) for chlordiazepoxide/clidinium products prescribed to treat various stomach and intestinal conditions.

• Bausch Health Companies Inc. Completes Name Change

  7/13/2018

  Bausch Health Will Begin Trading as "BHC" on NYSE and TSX on Monday, July 16

• Bausch + Lomb Announces U.S. FDA Filing Acceptance For Loteprednol Etabonate Ophthalmic Gel, 0.38%

  7/9/2018

  Bausch + Lomb announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for its sub-micron loteprednol etabonate ophthalmic gel

• 

  Adamis Pharma Sells Epinephrine Injector Rights to Novartis

  7/2/2018

  Adamis Pharmaceuticals is selling U.S. commercial rights to Symjepi, a competitor to Mylan’s EpiPen, to Novartis.
• 

  Sprout Relaunches Female Sex Drive Pill Addyi at Half the Price Charged Under Valeant

  6/28/2018

  After failing to gain market share under the umbrella of Valeant Pharmaceuticals, Addyi is getting a relaunch at half the price.
• 

  FDA Hits Valeant’s Plaque Psoriasis Drug with a Complete Response Letter

  6/19/2018

  Ortho Dermatologics, a division of Quebec-based Valeant Pharmaceuticals International, received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Duobrii for plaque psoriasis.

• FDA Issues Complete Response Letter For DUOBRII™ (Halobetasol Propionate and Tazarotene) Lotion

  6/18/2018

  Ortho Dermatologics announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the company's New Drug Application (NDA) for DUOBRII™1 (halobetasol propionate and tazarotene) (IDP-118) lotion in the treatment of plaque psoriasis.

• Bausch + Lomb Launches Soothe® Xtra Protection Preservative Free Lubricant Eye Drops

  6/14/2018

  Bausch + Lomb announced the introduction of Soothe® Xtra Protection (XP) Preservative Free lubricant eye drops

• Bausch + Lomb Introduces Ocuvite® Blue Light Eye Vitamins

  6/12/2018

  Bausch + Lomb announced the introduction of Ocuvite® Blue Light eye vitamins

• Argentum Pharmaceuticals Wins Patent Invalidation Trial Against Patent on Valeant's JUBLIA®

  6/8/2018

  On June 6, 2018, the U.S. Patent & Trademark Office issued a final written decision in favor of Argentum Pharmaceuticals, finding all claims of U.S. Patent No. 7,214,506 to be unpatentable for obviousness.

• 

  Carl Icahn Building Stake in Allergan Amidst Management Criticism

  6/7/2018

  After two of Allergan’s investors, Appaloosa Management and Senator Investment Group, wrote to the company’s board asking that Brent Saunders’ duties be split up, legendary investor Carl Icahn appears to be building a position in the company—again.

• Valeant Announces Closing Of Amended And Restated Credit Agreement Transaction And Senior Notes Offering, As Well As Redemption Of Existing Senior Notes

  6/1/2018

  Valeant Pharmaceuticals International, Inc. announced that it has entered into a Fourth Amended & Restated Credit and Guaranty Agreement effectuating a full refinancing of its secured revolving and term loan credit facilities, and closed the previously announced offering of 8.500% Senior Notes due 2027.

• Salix To Highlight New Clinical Data During Digestive Disease Week

  5/31/2018

  Salix Pharmaceuticals will present new scientific data, including one podium presentation and eight posters evaluating investigative data on the safety and efficacy of XIFAXAN® (rifaximin) and PLENVU® (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution) at Digestive Disease Week (DDW).